Imugene announced termination of its supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA. Imugene is continuing with its clinical trial to evaluate the safety and efficacy with the use of Imugene's HER-Vaxx, a B-cell activating immunotherapy in patients with HER-2 positive gastric cancer in combination with anti-PD-1 therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.079 AUD | -4.82% | +11.27% | -28.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.18% | 395M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Imugene Limited Announces Termination of Supply Agreement